Name | Number of supported studies | Average coverage | |
---|---|---|---|
cardiac muscle cell | 5 studies | 33% ± 6% |
Insufficient scRNA-seq data for expression of TRIM55 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 96% | 1173.19 | 218 / 226 | 71% | 31.78 | 289 / 406 |
kidney | 76% | 276.98 | 68 / 89 | 85% | 18.40 | 766 / 901 |
muscle | 100% | 1838.03 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 4139.52 | 835 / 861 | 0% | 0 | 0 / 0 |
thymus | 2% | 3.24 | 12 / 653 | 30% | 1.43 | 181 / 605 |
adrenal gland | 0% | 0 | 0 / 258 | 16% | 1.54 | 37 / 230 |
brain | 14% | 34.12 | 370 / 2642 | 0% | 0 | 0 / 705 |
lung | 2% | 7.23 | 9 / 578 | 10% | 0.70 | 110 / 1155 |
uterus | 2% | 8.36 | 4 / 170 | 8% | 4.33 | 38 / 459 |
lymph node | 0% | 0 | 0 / 0 | 10% | 1.27 | 3 / 29 |
ovary | 0% | 0 | 0 / 180 | 9% | 0.38 | 39 / 430 |
breast | 1% | 3.06 | 4 / 459 | 6% | 1.08 | 67 / 1118 |
skin | 6% | 18.67 | 106 / 1809 | 1% | 0.33 | 4 / 472 |
tonsil | 0% | 0 | 0 / 0 | 7% | 0.26 | 3 / 45 |
prostate | 4% | 12.75 | 10 / 245 | 2% | 0.09 | 9 / 502 |
blood vessel | 4% | 17.96 | 51 / 1335 | 0% | 0 | 0 / 0 |
esophagus | 0% | 0.66 | 4 / 1445 | 2% | 0.39 | 3 / 183 |
bladder | 0% | 0 | 0 / 21 | 2% | 0.11 | 9 / 504 |
pancreas | 0% | 0 | 0 / 328 | 2% | 0.23 | 3 / 178 |
adipose | 1% | 2.60 | 12 / 1204 | 0% | 0 | 0 / 0 |
stomach | 0% | 0.52 | 1 / 359 | 1% | 0.18 | 2 / 286 |
peripheral blood | 1% | 1.60 | 7 / 929 | 0% | 0 | 0 / 0 |
spleen | 0% | 0.55 | 1 / 241 | 0% | 0 | 0 / 0 |
intestine | 0% | 0.14 | 1 / 966 | 0% | 0.02 | 1 / 527 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_0016567 | Biological process | protein ubiquitination |
GO_0002523 | Biological process | leukocyte migration involved in inflammatory response |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
GO_0050904 | Biological process | diapedesis |
GO_1905517 | Biological process | macrophage migration |
GO_0005874 | Cellular component | microtubule |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0030674 | Molecular function | protein-macromolecule adaptor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | TRIM55 |
Protein name | Tripartite motif-containing protein 55 (EC 2.3.2.27) (Muscle-specific RING finger protein 2) (MuRF-2) (MuRF2) (RING finger protein 29) |
Synonyms | MURF2 RNF29 |
Description | FUNCTION: E3 ubiquitin ligase that plays an important role in regulating cardiac development and contractility, muscle growth, metabolism, and fiber-type differentiation. Acts as a critical factor that regulates cardiomyocyte size during development in concert with TRIM63 by regulating E2F1-mediated gene expression (By similarity). Plays a role in apoptosis induction in cardiomyocytes by promoting ubiquitination of the DUSP1 phosphatase. Promotes non-canonical NF-kappa-B signaling and B-cell-mediated immune responses by mediating NFKB2 'Lys-48'-linked ubiquitination and processing. In turn, NFKB2 is further processed by valosin-containing protein/VCP, an ATPase that mediates ubiquitin-dependent protein degradation by the proteasome. May play a role in preventing macrophages from producing inflammatory factors and migrating by downregulating the level of nuclear NF-kappa-B subunit RELA. Modifies also PPARG via polyubiquitination and accelerates PPARG proteasomal degradation to inhibit its activity . . |
Accessions | ENST00000315962.9 [Q9BYV6-1] Q9BYV6 ENST00000353317.9 [Q9BYV6-2] ENST00000276573.11 [Q9BYV6-3] ENST00000350034.4 [Q9BYV6-4] |